BAKER BROS. ADVISORS LP Portfolio

Auto-discovered 13F filer (Top-2000 by latest reported value).

SEC 13F CIK: 0001263508

What is a 13F filing? Who files one and when · What 13F filings can't tell you

LargeFocusedHealth TiltHigh Turnover how tags are computed

Q3 2026 · 78 positions · Total reported value $20.65B · Top-10 concentration 78.7% · Updated 2026-11-17

Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR

Turnover: 25.6% · 3 new · 11 cut · 8 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): +11.1% · vs SPY +9.0% · Prev Value $19.13B — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -0.9% · vs SPY -3.1% · Latest Value $20.65B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, BAKER BROS. ADVISORS LP disclosed 78 equity positions with a combined reported value of $20.65B. The filing implies a focused portfolio: its ten largest positions account for 78.7% of reported value. HoldingsHub classifies the profile as Large / Focused / Health Tilt / High Turnover.

The largest disclosed positions as of Q3 2026 were INCY ($3.73B), ONC ($3.23B), RVMD ($2.18B). By sector, the heaviest allocations are Health Care 99.9%, Other 0.1%. Versus the prior quarter, allocation shifted toward Health Care (+0.5pp) and away from Other (-0.5pp).

Versus the prior quarter, BAKER BROS. ADVISORS LP opened 3 new positions, trimmed 11 and fully exited 8, a turnover rate of 25.6% of positions. The portfolio's overlap with the prior quarter was 87% of names.

The largest new positions opened in Q3 2026 were TRAX ($16.76M), SYRE ($12.68M), QTTB ($4.53M).

Of the 8 positions fully exited versus the prior quarter, the largest were CRNX ($87.99M), ALMS ($56.63M), VRDN ($43.78M).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • TRAX FIRST TRACKS BIOTHERAPEUTICS · $16.76M
  • SYRE SPYRE THERAPEUTICS INC · $12.68M
  • QTTB Q32 BIO INC · $4.53M

Fully Exited (vs previous quarter)

  • CRNX CRINETICS PHARMACEUTICALS IN · prev qtr: $87.99M
  • ALMS ALUMIS INC · prev qtr: $56.63M
  • VRDN VIRIDIAN THERAPEUTICS INC · prev qtr: $43.78M
  • SION SIONNA THERAPEUTICS INC · prev qtr: $17.60M
  • VSTM VERASTEM INC · prev qtr: $9.55M
  • SGMT SAGIMET BIOSCIENCES INC · prev qtr: $7.37M
  • WVE WAVE LIFE SCIENCES INC · prev qtr: $4.78M
  • SRZNW SURROZEN INC · prev qtr: $13.75K

Insider Transactions (Form 4)

Latest BAKER BROS. ADVISORS LP buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

Transaction date Activity Security Shares Price Filing
2026-11-06 Buy MADRIGAL PHARMACEUTICALS, INC. 2,000 $396.61 SEC filing
2026-11-06 Buy MADRIGAL PHARMACEUTICALS, INC. 13,740 $388.29 SEC filing
2026-11-06 Buy MADRIGAL PHARMACEUTICALS, INC. 60,400 $383.01 SEC filing
2026-11-05 Buy Kodiak Sciences Inc. 81,729 $98.51 SEC filing
2026-11-05 Buy Kodiak Sciences Inc. 4,703 $98.51 SEC filing
2026-11-04 Buy Kodiak Sciences Inc. 151,916 $98.51 SEC filing
2026-11-04 Buy Kodiak Sciences Inc. 8,742 $98.51 SEC filing
2026-11-04 Buy MADRIGAL PHARMACEUTICALS, INC. 10,080 $368.11 SEC filing

All insider transactions →

Fund Profile

Baker BROS. Advisors is an SEC-registered 13F filer based in New York, NY, United States. As of Q3 2026 it reported 78 US equity positions with a combined value of $20.65B. HoldingsHub carries 13 quarters of its filings (Q3 2023–Q3 2026).

Firm Snapshot

  • Headquarters: NEW YORK, NY, United States
  • SEC registration: 801-73446 (status: Approved), registered 2012-03-05
  • Regulatory AUM (Form ADV): $28.15B as of 2026-03-27
  • Client mix (by RAUM): pension and profit-sharing plans 100%
  • Manages 2 private funds, of which 2 hedge funds

Portfolio Structure

  • 78 positions · $20.65B reported value (Q3 2026)
  • Top 10 holdings = 78.7% of reported value
  • Largest position: INCY (INCYTE CORP) at 18.1%
  • Average position size: $264.73M

Sector Tilt

  • Health Care 99.9%
  • (classified holdings cover 100% of value)

Quarterly Activity

  • Q3 2026: 3 new, 6 added, 11 reduced, 8 exited
  • 58 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall direction and market view: The fund is actively rebalancing with a bullish tilt on select biotech/healthcare names, increasing exposure to Kodiak Sciences (KOD) while trimming Revolution Medicines (RVMD), suggesting a tactical shift toward higher-conviction positions. 2. Key moves: - Added: Kodiak Sciences (KOD) significantly (6.0% weight increase, +9.7% shares). - Reduced: Revolution Medicines (RVMD) moderately (0.6% weight decrease, -7.0% shares). - Holdings: No other adds/reductions; weight changes driven by price action (e.g., ONC, GRAL). 3. Portfolio structure: Highly active, concentrated in healthcare (100% top 10), with high single-name risk (top 3 holdings = 44.3% weight). Aggressive growth focus, likely targeting clinical-stage biotech catalysts. 4. Per-holding one-liner: - INCY: InCyte Corp (unverified: oncology/hematology drugs). - ONC: BeOne Medicines Ltd (unverified: oncology therapeutics). - RVMD: Revolution Medicines Inc (unverified: KRAS inhibitors). - KOD: Kodiak Sciences Inc (unverified: eye disease therapies). - MDGL: Madrigal Pharmaceuticals (unverified: metabolic disease drugs). - INSM: Insmed Inc (unverified: rare lung diseases). - KYMR: Kymera Therapeutics (unverified: inflammation/immunology). - ACAD: Acadia Pharmaceuticals (unverified: Parkinson’s psychosis). - GRAL: Grail Inc (unverified: early cancer detection). - SMMT: Summit Therapeutics (unverified: muscular dystrophy). 5. Style summary: Concentrated healthcare fund tactically rotating into Kodiak Sciences while trimming Revolution Medicines, maintaining a high-conviction, growth-oriented biotech bias.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice. · AI generated 2026-11-17 09:22

Sector Allocation

Health Care 99.9%
Other 0.1%
Sort by: Value · CSV
# Shares Value Weight Allocation Change
1 30.76M $3.73B 18.08%
Form 4 · 1 →
18.08%
Hold
2 8.83M $3.23B 15.65%
15.65%
Hold
3 10.64M $2.18B 10.57%
10.57%
Reduce
4 21.86M $2.07B 10.04%
Form 4 · 86 →
10.04%
Add
5 2.14M $1.08B 5.23%
Form 4 · 5 →
5.23%
Hold
6 8.80M $1.00B 4.86%
4.86%
Hold
7 8.66M $967.79M 4.69%
4.69%
Hold
8 42.91M $864.70M 4.19%
4.19%
Hold
9 4.03M $564.49M 2.73%
2.73%
Hold
10 32.79M $554.42M 2.69%
2.69%
Hold
11 5.60M $533.63M 2.58%
2.58%
Hold
12 1.75M $510.58M 2.47%
2.47%
Hold
13 33.01M $481.65M 2.33%
2.33%
Hold
14 10.01M $405.70M 1.97%
1.97%
Hold
15 2.83M $211.49M 1.02%
1.02%
Hold
16 5.01M $192.49M 0.93%
0.93%
Hold
17 3.70M $150.29M 0.73%
0.73%
Hold
18 11.05M $146.24M 0.71%
0.71%
Hold
19 3.66M $133.86M 0.65%
0.65%
Reduce
20 1.71M $111.86M 0.54%
0.54%
Reduce
21 4.66M $110.45M 0.54%
0.54%
Hold
22 2.77M $93.58M 0.45%
0.45%
Reduce
23 2.56M $83.13M 0.40%
0.40%
Add
24 3.73M $77.19M 0.37%
0.37%
Hold
25 852.16K $75.03M 0.36%
0.36%
Hold
26 30.75M $55.46M 0.27%
0.27%
Hold
27 1.55M $51.98M 0.25%
0.25%
Hold
28 4.35M $51.84M 0.25%
0.25%
Hold
29 2.83M $51.02M 0.25%
0.25%
Hold
30 1.02M $45.72M 0.22%
0.22%
Reduce
31 1.43M $44.80M 0.22%
0.22%
Hold
32 905.19K $41.49M 0.20%
0.20%
Hold
33 10.89M $40.06M 0.19%
0.19%
Hold
34 10.12M $39.58M 0.19%
0.19%
Hold
35 445.98K $38.12M 0.18%
0.18%
Hold
36 2.99M $37.56M 0.18%
0.18%
Add
37 4.26M $37.37M 0.18%
0.18%
Reduce
38 1.31M $34.16M 0.17%
0.17%
Reduce
39 5.07M $32.21M 0.16%
0.16%
Hold
40 991.69K $27.59M 0.13%
0.13%
Hold
41 1.10M $27.50M 0.13%
0.13%
Hold
42 803.42K $23.89M 0.12%
0.12%
Reduce
43 2.13M $22.99M 0.11%
0.11%
Hold
44 349.66K $22.89M 0.11%
0.11%
Hold
45 844.82K $21.82M 0.11%
0.11%
Hold
46 1.42M $21.38M 0.10%
0.10%
Hold
47 4.00M $19.50M 0.09%
0.09%
Hold
48 996.35K $19.40M 0.09%
0.09%
Hold
49 1.23M $17.29M 0.08%
0.08%
Hold
50 1.46M $17.19M 0.08%
0.08%
Hold

FAQ

What did BAKER BROS. ADVISORS LP buy in 2026-Q3?

In its 2026-Q3 13F filing, BAKER BROS. ADVISORS LP reported 78 equity positions worth $20.65B in aggregate; its largest disclosed positions were INCY ($3.73B), ONC ($3.23B), RVMD ($2.18B).

How large is BAKER BROS. ADVISORS LP's portfolio?

BAKER BROS. ADVISORS LP reported $20.65B of long equity holdings across 78 positions as of 2026-Q3. Top-10 holdings account for 78.7% of reported value.

What is BAKER BROS. ADVISORS LP's investment style?

HoldingsHub classifies the portfolio as Large / Focused / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/baker-bros-advisors/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →